Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Researchers are assessing a drug called rQNestin34.5v.2, for people with brain cancer that came back after treatment. The people in this study have a type of brain cancer called a glioma.
CAR T-cell therapies are a form of immunotherapy where some of a patient's T cells are removed, modified in the laboratory to recognize a protein on cancer cells, multiplied, and returned to the patient to provoke an immune attack against cancer. Sometimes the new T cells cause side effects related to the immune system's response to the treatment.
Researchers want to see how well revumenib works when given with chemotherapy to treat infant leukemia. The children in this study have acute leukemia that came back or keeps growing even after treatment. The leukemia has a gene rearrangement (genetic change) called KMT2A-R.
Researchers want to see if adding radiation therapy to standard medical treatments works better than standard therapies alone in people with kidney cancer. The standard therapies include:
Researchers want to find the best dose of lorlatinib to give with ramucirumab in people with lung cancer. They are also seeing how well this drug combination works. The people in this study have non-small cell lung cancer (NSCLC) that has metastasized (spread). In addition, their cancers have a fusion involving the ALK gene. A fusion gene is made when parts of two different genes in your body join together.
In this study, researchers are assessing the safety of the drug lurbinectedin in young people with solid tumors. In the first part, they will find the highest dose of lurbinectedin to use safely in children with solid tumors. If your child joins, this is the part of the study they will be in.
Researchers are comparing two treatments for people with non-muscle invasive bladder cancer. If you take part in this study, you will be randomly assigned to get either:
This study is evaluating the safety and effectiveness of combination chemotherapy, surgery, and radiation therapy in children and young adults with newly diagnosed stage II-IV diffuse anaplastic Wilms' tumors (DAWT) or favorable histology Wilms' tumors (FHWT) that have come back (relapsed).
Researchers are assessing the best dose and benefit of DT2216 given with irinotecan chemotherapy in young people with cancer. DT2216 may help to kill cancer cells by blocking Bcl-xL, a protein that some cancers need to survive. Irinotecan is an anti-cancer drug that is part of the usual treatment for many cancers. Both drugs are given intravenously (by vein).
